Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Albumin ratio

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
CSF
Biomarker Measured
Amyloid
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

The ratio of albumin protein in the cerebrospinal fluid compared to levels in the plasma or serum was slightly higher in people with Alzheimer’s disease than in controls (effect size = 1.103, p = 0.02564). The effect was marginal. The albumin ratio is considered a measure of blood-brain barrier function.

What is Required from Patients

blood draw, invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physician who can preform a lumbar puncture as well as a clinic designed for this testing, phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Data collected by multiple groups. Alzforum meta analysis.

  1. “Alzheimer's Disease vs Control: albumin ratio (CSF/Serum and/or Plasma)”. Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-albumin-ratio-csfserum-andor-plasma

  2. Chalbot, S., Zetterberg, H., Blennow, K., Fladby, T., Andreasen, N., Grundke-Iqbal, I., & Iqbal, K. (2011). Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. Journal of Alzheimer's Disease, 25(3), 505-515. https://www.ncbi.nlm.nih.gov/pubmed/21471645

  3. Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., ... & Wu, E. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology, 15(7), 673-684. https://www.ncbi.nlm.nih.gov/pubmed/27068280